No Data
No Data
Wolfe Research Upgrades Qiagen NV(QGEN.US) to Buy Rating, Announces Target Price $50
Wolfe Research analyst Doug Schenkel upgrades $Qiagen NV(QGEN.US)$ to a buy rating, and sets the target price at $50.According to TipRanks data, the analyst has a success rate of 65.6% and a total ave
FDA Approves Bristol Myers Squibb's Combination Therapy For Colorectal Cancer Patients With Certain Type Of Gene Mutation
Friday, the FDA granted accelerated approval to Bristol Myers Squibb & Co's (NYSE:BMY) Krazati (adagrasib) in combination with cetuximab as a targeted treatment option for adult patients with KRASG12C
CORRECTION : JP Morgan Maintains Overweight on Qiagen, Raises Price Target to $54 -Analyst Name Updated (Article Originally Published on 18th June)
CORRECTION : JP Morgan analyst Casey Woodring maintains Qiagen (NYSE:QGEN) with a Overweight and raises the price target from $52 to $54 -Analyst Name Updated (Article Originally Published on 18th Jun
Qiagen on Pace for Largest Percent Decrease Since October 2022 -- Data Talk
QIAGEN NV (QGEN) is currently at $41.82, down $1.93 or 4.4% --Would be lowest close since April 26, 2024, when it closed at $41.65 --On pace for largest percent decrease since Oct. 19, 2022, when it
Vanda Pharmaceuticals And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 100 points on Thursday.Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) fell sharply in today's pre-market trading
J.P. Morgan Maintains Qiagen NV(QGEN.US) With Buy Rating, Raises Target Price to $54
J.P. Morgan analyst Casey Woodring maintains $Qiagen NV(QGEN.US)$ with a buy rating, and adjusts the target price from $52 to $54.According to TipRanks data, the analyst has a success rate of 40.5% an